Clinical Trial Update: Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating PAZ-417 in cerebrospinal fluid for Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PAZ-417

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 1 | Status: TERMINATED